- cafead   Nov 18, 2020 at 11:32: PM
via A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back their upstart approach for a rare genetic condition called hereditary angioedema, or HAE.
article source
article source